The development of inhibitory antibodies to therapeutic factor VIII is the major complication of replacement therapy in patients with hemophilia A. The first step in the initiation of the anti-factor VIII immune response is factor VIII interaction with receptor(s) on antigen-presenting cells， followed by endocytosis and presentation to na?ve CD4 T cells. Recent studies indicate a role for the C1 domain in factor VIII uptake. We investigated whether charged residues in the C2 domain participate in immunogenic factor VIII uptake. Co-incubation of factor VIII with BO2C11， a monoclonal C2-specific immunoglobulin G， reduced factor VIII endocytosis by dendritic cells and presentation to CD4 T cells， and diminished factor VIII immunogenicity in factor VIII-deficient mice. The mutation of basic residues within the BO2C11 epitope of C2 replicated reduced in vitro immunogenic uptake， but failed to prevent factor VIII immunogenicity in mice. BO2C11 prevents factor VIII binding to von Willebrand factor， thus potentially biasing factor VIII immunogenicity by perturbing its half-life. Interestingly， a factor VIII mutant， that does not bind von Willebrand factor， demonstrated unaltered endocytosis by dendritic cells as well as immunogenicity in factor VIII-deficient mice. Co-incubation of factor VIII with BO2C11， however， resulted in decreased factor VIII immunogenicity in vivo In addition， a previously described triple C1 mutant showed decreased uptake in vitro， and reduced immunogenicity in vivo， but only in the absence of endogenous von Willebrand factor. Taken together， the results indicate that residues in the C1 and/or C2 domains of factor VIII are implicated in immunogenic factor VIII uptake， at least in vitro Conversely， in vivo， the binding to endogenous von Willebrand factor masks the reducing effect of mutations in the C domains on factor VIII immunogenicity.